Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion type Assertion NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_head.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion wasGeneratedBy ECO_0000203 NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_provenance.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion wasDerivedFrom befree-2016 NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_provenance.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion SIO_000772 21430781 NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_provenance.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion evidence source_evidence_literature NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_provenance.
- NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_assertion description "[Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881854.RAA5IVdldYaa9EV-LA34ZK0ZeCxtGSKhwA5XD5LuqmCmY130_provenance.